Daehan Nupharm Co., Ltd.

As of March 31, 2026, Daehan Nupharm Co., Ltd. carries a market capitalization of 98.39B, placing it among publicly traded companies globally. Its enterprise value stands at 172.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Daehan Nupharm Co., Ltd. has 14.04M shares outstanding.

As of March 31, 2026, Daehan Nupharm Co., Ltd. trades at a trailing price-to-earnings ratio of 6.28. The price-to-sales ratio is 0.48, and the price-to-book ratio stands at 0.71.

As of March 31, 2026, Daehan Nupharm Co., Ltd. trades at an EV/EBITDA multiple of 11.51 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 172.55B versus a market cap of 98.39B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Daehan Nupharm Co., Ltd. maintains a current ratio of 1.57, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 77.82, indicating elevated leverage, while an interest coverage ratio of 8.72 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Daehan Nupharm Co., Ltd. posted a return on equity (ROE) of 11.85, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 6.15, measuring how efficiently the asset base is converted into earnings. The company generates approximately 519.97M in revenue per employee across its workforce of 395.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.78 indicates how many times Daehan Nupharm Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Daehan Nupharm Co., Ltd. recorded an income tax benefit of -513.72M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 15.16B, leaving 15.68B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Daehan Nupharm Co., Ltd.'s stock has declined approximately 22.19% over the past 52 weeks. The 50-day moving average sits at 5,578.40, while the 200-day moving average is 6,178.10.

Over the twelve months ended March 31, 2026, Daehan Nupharm Co., Ltd. generated 205.39B in revenue and converted that into 15.68B in net income, yielding earnings per share of 1,116.99. EBITDA reached 15.00B, while operating income came in at 10.62B.

As of March 31, 2026, Daehan Nupharm Co., Ltd. holds 33.38B in cash and equivalents against 107.55B in total debt, resulting in a net debt position of 87.75B. Total book value stands at 138.21B, with working capital of 43.02B providing operational flexibility.

Daehan Nupharm Co., Ltd. produced 1.96B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -44.06B in capital expenditures, free cash flow totaled -42.11B - equivalent to -3,000.05 per share.

Over the twelve months ended March 31, 2026, Daehan Nupharm Co., Ltd. posted a gross margin of 44.26, reflecting its pricing power and cost economics. The operating margin of 5.17 and net profit margin of 7.63 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, Daehan Nupharm Co., Ltd. paid dividends of 100.00 per share. The dividend payout ratio of 8.95 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -42.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -36.21, meaning Daehan Nupharm Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Daehan Nupharm Co., Ltd.'s most recent stock split took place on November 28, 2005 with a 579:602 split ratio.

As of March 31, 2026, Daehan Nupharm Co., Ltd. has an Altman Z-Score of 1.87, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.